Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.
about
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataPfCRT and its role in antimalarial drug resistanceChloroquine is grossly under dosed in young children with malaria: implications for drug resistanceThe Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line TherapiesMultiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sitesDiverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporterA cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo.Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortalityArtemether-lumefantrine: an option for malaria.Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial.Validation of a chloroquine-induced cell death mechanism for clinical use against malariaRational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Quantifying the pharmacology of antimalarial drug combination therapy.Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine.High-Dose Chloroquine for Treatment of Chloroquine-Resistant Plasmodium falciparum Malaria.Is chloroquine making a comeback?Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
P2860
Q26783646-CD44781F-7129-4569-86C7-89D4C5947AD3Q27861957-06377C7B-C5EB-45B7-AC34-B807722ADB0DQ28539103-D1F76ADE-E12E-4906-BCDD-E0973EC0042AQ28551049-E2E97832-FDF2-477C-9F05-29313465B0C2Q30041687-FAA61AA5-0FDA-49E7-BC84-BE4DE26DD6A6Q33674606-9304CFA6-F1D5-4488-9044-ED78BD919474Q33719592-BA88019F-393C-404A-BC77-399575C55D5FQ33830762-D434588D-E56C-4352-879A-BC782D1FE08CQ34267667-58C9FD71-98C4-47D6-B1F9-A949FAAB96AFQ34299078-7F9B7BC5-F11F-45C4-80DD-5A7F023099D8Q35105975-8BF77FEF-6EEF-4540-9104-87E2521E05BAQ35139464-F2F0B015-EFE0-4C7F-8F8F-D0771B9A42D5Q35205935-6D6FE556-55D6-4550-993A-083BF2F52F38Q35941244-05327FB9-8040-42AE-A29C-50E7ADB51FC8Q36138583-03961A81-14AC-4F70-AAE3-9A6BB68BFA23Q36179646-74A6EC7C-2CA2-4D1A-9259-0D1B79B8686CQ36617963-EB620399-828B-42C5-AA1D-0B9351C82A27Q37279764-21D951E1-21A9-4C47-8457-E3409B437FB9Q37283299-0F2C15CA-4462-48D6-A4B7-286E5AB1BC52Q37685088-6CDE035C-C9EF-47DE-860B-B26503E550F1Q37979631-9AA83CB2-8B32-49A3-99C8-65547A9CD86DQ38225084-CCD691E6-4786-477B-BA63-049CC7A8781BQ38529669-BAF2C365-B82B-4605-9229-A988EDD5BB9DQ40223323-6600B8B8-0F1E-4832-8E13-7635229EC880Q42725873-82039387-370C-49B0-8EEF-13E53523DC52Q55449589-FD34713A-68F3-4951-9569-BFA038E47F7A
P2860
Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@ast
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@en
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@nl
type
label
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@ast
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@en
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@nl
prefLabel
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@ast
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@en
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@nl
P2093
P2860
P921
P356
P1476
Similar efficacy and tolerabil ...... ea-Bissau: a randomized trial.
@en
P2093
Amabelia Rodrigues
Daniel Blessborn
Lars Rombo
Poul-Erik Kofoed
Rikke Thoft-Nielsen
P2860
P304
P356
10.1093/INFDIS/JIQ001
P407
P577
2011-01-01T00:00:00Z